Nothing new today. The sweep found no fresh approvals, safety communications, recalls or guideline releases relevant to cardiology, and the FDA feeds returned no cardiology items at all.
The most useful recent document for the desk remains the 2025 American College of Cardiology scientific statement on peripheral artery disease in adults with diabetes. Its central observation is a diagnostic failure rather than a therapeutic one: many people with diabetes never get the classic claudication history, so peripheral artery disease goes undetected until it presents as chronic limb-threatening ischaemia, and amputation rates in this group are disproportionately high. The statement also notes that guideline-directed medical therapy is underused in exactly the patients who stand to gain most from it.
That is worth carrying into a cardiology clinic rather than leaving to the diabetes team. The patient in front of you with coronary disease and diabetes has a high prior probability of peripheral disease, will probably not volunteer leg symptoms, and is unlikely to be on the antithrombotic and lipid regimen the evidence supports for peripheral disease. In Indian practice, where diabetic neuropathy is common and often masks ischaemic pain entirely, waiting for symptoms is close to a guarantee of late diagnosis. Feel the pulses, and where they are diminished or the history is unclear, measure an ankle-brachial index.
- No new approvals, recalls or safety communications for cardiology today.
- Assume peripheral artery disease can be present without claudication in patients with diabetes.
- Examine foot pulses in every diabetic cardiology patient and measure an ankle-brachial index when they are diminished.
- Check that patients with known peripheral disease are actually on guideline-directed lipid and antithrombotic therapy.
- Neuropathy masks ischaemic leg pain, so absence of symptoms is not reassurance.
The statistics, in plain English
This is a scientific statement rather than a trial or a formal guideline. It gathers existing recommendations and adds consensus where the evidence is thin, so its authority comes from expert agreement rather than from new data. The document itself identifies the open questions — the best timing and method of screening, and how to standardise endpoints in peripheral artery disease trials — which is a fair signal of how much here is settled and how much is not.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for cardiology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free